295 related articles for article (PubMed ID: 22330049)
1. Redesign of glycopeptide antibiotics: back to the future.
James RC; Pierce JG; Okano A; Xie J; Boger DL
ACS Chem Biol; 2012 May; 7(5):797-804. PubMed ID: 22330049
[TBL] [Abstract][Full Text] [Related]
2. Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.
Wu ZC; Boger DL
Acc Chem Res; 2020 Nov; 53(11):2587-2599. PubMed ID: 33138354
[TBL] [Abstract][Full Text] [Related]
3. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.
Yoshida O; Yasukata T; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
Bioorg Med Chem Lett; 2002 Nov; 12(21):3027-31. PubMed ID: 12372494
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.
Miura K; Yamashiro H; Uotani K; Kojima S; Yutsudo T; Lu J; Yoshida O; Yamano Y; Maki H; Arimoto H
Antimicrob Agents Chemother; 2010 Feb; 54(2):960-2. PubMed ID: 19933802
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
Boneca IG; Chiosis G
Expert Opin Ther Targets; 2003 Jun; 7(3):311-28. PubMed ID: 12783569
[TBL] [Abstract][Full Text] [Related]
6. [Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)].
Kuwahara K; Hanaki H; Hiramatsu K
Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):182-5. PubMed ID: 10088368
[No Abstract] [Full Text] [Related]
7. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.
Michel M; Gutmann L
Lancet; 1997 Jun; 349(9069):1901-6. PubMed ID: 9217771
[TBL] [Abstract][Full Text] [Related]
8. Eremomycin pyrrolidide: a novel semisynthetic glycopeptide with improved chemotherapeutic properties.
Olsufyeva EN; Shchekotikhin AE; Bychkova EN; Pereverzeva ER; Treshalin ID; Mirchink EP; Isakova EB; Chernobrovkin MG; Kozlov RS; Dekhnich AV; Preobrazhenskaya MN
Drug Des Devel Ther; 2018; 12():2875-2885. PubMed ID: 30237697
[TBL] [Abstract][Full Text] [Related]
9. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.
Shetty N; Wilson AP
J Antimicrob Chemother; 2000 Oct; 46(4):633-8. PubMed ID: 11020265
[TBL] [Abstract][Full Text] [Related]
10. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
11. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
12. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management.
Noskin GA
Ann Acad Med Singap; 2001 May; 30(3):320-31. PubMed ID: 11455748
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01.
Shao C; Zhou W; Zhang S; Wei W; Ruan L; Jin Y; Sun X; Huang Y
Bioorg Med Chem Lett; 2011 Nov; 21(22):6732-8. PubMed ID: 21978682
[TBL] [Abstract][Full Text] [Related]
14. The specter of glycopeptide resistance: current trends and future considerations.
Moellering RC
Am J Med; 1998 May; 104(5A):3S-6S. PubMed ID: 9684651
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.
Bal AM; Gould IM
Expert Opin Pharmacother; 2005 Oct; 6(13):2257-69. PubMed ID: 16218886
[TBL] [Abstract][Full Text] [Related]
16. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.
Hsueh PR; Chen WH; Teng LJ; Luh KT
Int J Antimicrob Agents; 2005 Jul; 26(1):43-9. PubMed ID: 15975769
[TBL] [Abstract][Full Text] [Related]
17. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
18. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci.
Mohammad H; Mayhoub AS; Cushman M; Seleem MN
J Antibiot (Tokyo); 2015 Apr; 68(4):259-66. PubMed ID: 25315757
[TBL] [Abstract][Full Text] [Related]
19. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
20. Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.
Yoganathan S; Miller SJ
J Med Chem; 2015 Mar; 58(5):2367-77. PubMed ID: 25671771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
